Proxima
Last verified 2026-05-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $86.3Mattributed |
|---|---|
| Latest round | seed, $86.3M, 2026-01-01attributed |
| Founded | 2019 |
| Headquarters | New York |
| Industry | bio |
| Stage | seed |
| Website | proximabio.com |
Proxima is a biotech company with an AI-powered drug discovery platform focused on making protein interactions programmable through proximity modulators. It serves pharma and biotech partners, including Bristol Myers Squibb. Its differentiator is an integrated platform of three technologies built for the proximity modulator modality.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-01 | seed | $86.3M | undisclosed |
Detected tech stack
Vercel, Underscore.js, Next.js, React
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $86.3M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $86.3M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | proximabio.com, read 2026-05-13 |
| Description | self-reported | proximabio.com, read 2026-05-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.